IART logo

IART
Integra Lifesciences Holdings Corp

370
Mkt Cap
$1.25B
Volume
1.2M
52W High
$16.70
52W Low
$8.70
PE Ratio
-2.48
IART Fundamentals
Price
$16.04
Prev Close
$16.46
Open
$16.43
50D MA
$11.70
Beta
1.30
Avg. Volume
758,265.22
EPS (Annual)
-$6.74
P/B
1.20
Rev/Employee
$369,379.94
$2,721.71
Loading...
Loading...
News
all
press releases
Integra LifeSciences Holdings Corporation (IART) Hit a 52 Week High, Can the Run Continue?
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
News Placeholder
More News
News Placeholder
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon's Surgical and Vision Care units returned to 6% growth in Q1 2026, but tariffs, macro pressure and fierce competition still loom.
Zacks
News Placeholder
Is This the Right Time to Keep HSIC Stock in Your Portfolio?
Henry Schein is backed by a dental and medical distribution scale, digital dentistry push and acquisitions, but debt and macro headwinds weigh on its outlook.
Zacks
News Placeholder
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock
MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Zacks
News Placeholder
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.
Zacks
News Placeholder
Zacks.com featured highlights include DaVita, Integra LifeSciences, Braskem and LyondellBasell
DaVita, Integra, Braskem and LyondellBasell screen as attractive GARP stocks, combining growth potential with discounted PEG ratios.
Zacks
News Placeholder
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.
Zacks
News Placeholder
Omnicell Stock Surges 57.3% in a Year: What's Driving It?
OMCL shares soar 57.3% in a year as SaaS growth, Autonomous Pharmacy momentum and OmniSphere adoption boost outlook.
Zacks
News Placeholder
4 High-Growth GARP Stocks With Attractive PEG Ratios for 2026
These four GARP stocks combine discounted PEG ratios with strong growth potential, offering investors a balanced strategy for 2026.
Zacks
News Placeholder
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It PR Newswire NEW YORK, May 22, 2026 Issued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ...
PR Newswire
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available